Abstract：
BACKGROUND: Although umbilical cord mesenchymal stem cell (UCMSC) infusion has been proposed as a promising strategy for the treatment of acute lung injury (ALI), the parameters of UCMSC transplantation, such as infusion routes and doses, need to be further optimized.
METHODS: In this study, we compared the therapeutic effects of UCMSCs transplanted via intravenous injection and intratracheal instillation on lipopolysaccharide-induced ALI using a rat model. Following transplantation, levels of inflammatory factors in serum; neutrophils, total white blood cells, and lymphocytes in bronchoalveolar lavage fluid (BALF); and lung damage levels were analyzed.
RESULTS: The results indicated that UCMSCs administered via both intravenous and intratracheal routes were effective in alleviating ALI, as determined by analyses of arterial blood gas, lung histopathology, BALF contents, and levels of inflammatory factors. Comparatively, the intratracheal instillation of UCMSCs was found to result in lower levels of lymphocytes and total proteins in BALF, whereas greater reductions in the serum levels of tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) were detected in rats receiving intravenously injected stem cells.
CONCLUSIONS: Our findings in this study provide convincing evidence to indicate the efficacy of UCMSC therapy in the treatment of ALI mediated via different delivery routes, thereby providing a reliable theoretical basis for further clinical studies. Moreover, these findings imply that the effects obtained using the two assessed delivery routes for UCMSC transplantation are mediated via different mechanisms, which could be attributable to different cellular or molecular targets.
METHODS: In this study, we compared the therapeutic effects of UCMSCs transplanted via intravenous injection and intratracheal instillation on lipopolysaccharide-induced ALI using a rat model. Following transplantation, levels of inflammatory factors in serum; neutrophils, total white blood cells, and lymphocytes in bronchoalveolar lavage fluid (BALF); and lung damage levels were analyzed.
RESULTS: The results indicated that UCMSCs administered via both intravenous and intratracheal routes were effective in alleviating ALI, as determined by analyses of arterial blood gas, lung histopathology, BALF contents, and levels of inflammatory factors. Comparatively, the intratracheal instillation of UCMSCs was found to result in lower levels of lymphocytes and total proteins in BALF, whereas greater reductions in the serum levels of tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) were detected in rats receiving intravenously injected stem cells.
CONCLUSIONS: Our findings in this study provide convincing evidence to indicate the efficacy of UCMSC therapy in the treatment of ALI mediated via different delivery routes, thereby providing a reliable theoretical basis for further clinical studies. Moreover, these findings imply that the effects obtained using the two assessed delivery routes for UCMSC transplantation are mediated via different mechanisms, which could be attributable to different cellular or molecular targets.
摘要：
背景：尽管脐带间充质干细胞（UCMSC）输注已被提出作为治疗急性肺损伤（ALI）的有希望的策略，UCMSC移植的参数，如输注途径和剂量，需要进一步优化。
方法：在本研究中，我们使用大鼠模型比较了通过静脉注射和气管内滴注移植UCMSCs对脂多糖诱导的ALI的治疗效果。移植后,血清炎症因子水平;中性粒细胞,白细胞总数,和支气管肺泡灌洗液（BALF）中的淋巴细胞；并分析肺损伤水平。
结果：结果表明，通过静脉和气管内途径给予UCMSCs均可有效缓解ALI，通过动脉血气分析确定，肺组织病理学,BALF内容物,和炎症因子水平。相对而言,发现气管内滴注UCMSCs会导致BALF中淋巴细胞和总蛋白水平降低，而在接受静脉注射干细胞的大鼠中，血清肿瘤坏死因子α（TNF-α）和白细胞介素1β（IL-1β）水平降低更大。
结论：我们在这项研究中的发现提供了令人信服的证据，表明UCMSC治疗通过不同给药途径介导的ALI的疗效。从而为进一步的临床研究提供可靠的理论依据。此外，这些发现表明，使用两种评估的UCMSC移植递送途径获得的效果是通过不同的机制介导的，这可能归因于不同的细胞或分子靶标。
方法：在本研究中，我们使用大鼠模型比较了通过静脉注射和气管内滴注移植UCMSCs对脂多糖诱导的ALI的治疗效果。移植后,血清炎症因子水平;中性粒细胞,白细胞总数,和支气管肺泡灌洗液（BALF）中的淋巴细胞；并分析肺损伤水平。
结果：结果表明，通过静脉和气管内途径给予UCMSCs均可有效缓解ALI，通过动脉血气分析确定，肺组织病理学,BALF内容物,和炎症因子水平。相对而言,发现气管内滴注UCMSCs会导致BALF中淋巴细胞和总蛋白水平降低，而在接受静脉注射干细胞的大鼠中，血清肿瘤坏死因子α（TNF-α）和白细胞介素1β（IL-1β）水平降低更大。
结论：我们在这项研究中的发现提供了令人信服的证据，表明UCMSC治疗通过不同给药途径介导的ALI的疗效。从而为进一步的临床研究提供可靠的理论依据。此外，这些发现表明，使用两种评估的UCMSC移植递送途径获得的效果是通过不同的机制介导的，这可能归因于不同的细胞或分子靶标。
